Shigehira Saji

Summary

Country: Japan

Publications

  1. ncbi request reprint Trastuzumab: updates and future issues
    Masakazu Toi
    Department of Clinical Trial and Research, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Honkomagome 3 18 22, Bunkyo ku, Tokyo, 113 8677, Japan
    Cancer Chemother Pharmacol 56:94-9. 2005
  2. ncbi request reprint Current status of antibody therapy for breast cancer
    Masakazu Toi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Breast Cancer 11:10-4. 2004
  3. ncbi request reprint Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study
    Reiko Suzuki
    Division of Nutritional Epidemiology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 119:1683-9. 2006
  4. ncbi request reprint Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol
    S Saji
    2nd Department of Surgery, Gifu University School of Medicine
    Jpn J Cancer Res 90:210-8. 1999
  5. pmc Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane
    Shigehira Saji
    Department of Target Therapy Oncology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto, 606 8507, Japan
    BioDrugs 27:469-78. 2013
  6. ncbi request reprint Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer
    Shigehira Saji
    Department of Clinical Trials and Research, Breast Surgery, Tokyo Metropolitan Komagome Hospital, Honkomagome, Tokyo, Japan
    Oncogene 24:4531-9. 2005
  7. ncbi request reprint Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer
    Shigehira Saji
    Department of Surgery and Breast Oncology, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Breast Cancer 11:129-33. 2004
  8. ncbi request reprint Clinical impact of assay of estrogen receptor beta cx in breast cancer
    Shigehira Saji
    Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Breast Cancer 9:303-7. 2002
  9. ncbi request reprint Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor
    Shigehira Saji
    Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, 113 8677 Tokyo, Japan
    Cancer Res 62:4849-53. 2002
  10. doi request reprint Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells
    Mariko Muta
    Department of Health and Dietetics, Faculty of Medical Health, Teikyo Heisei University, Tokyo, Japan
    Oncology 77:182-91. 2009

Detail Information

Publications51

  1. ncbi request reprint Trastuzumab: updates and future issues
    Masakazu Toi
    Department of Clinical Trial and Research, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Honkomagome 3 18 22, Bunkyo ku, Tokyo, 113 8677, Japan
    Cancer Chemother Pharmacol 56:94-9. 2005
    ..It might also be important to investigate, with greater depth, the interaction between the Her-axis and the hormone-axis. This short review describes and discusses these topics...
  2. ncbi request reprint Current status of antibody therapy for breast cancer
    Masakazu Toi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Breast Cancer 11:10-4. 2004
    ..We reviewed recent advances in trastuzumab treatment and discuss the future of antibody therapy for breast cancer...
  3. ncbi request reprint Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study
    Reiko Suzuki
    Division of Nutritional Epidemiology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 119:1683-9. 2006
    ..82 (CI 95%:1.45-2.29)). Our results support the hypothesis that excess endogenous estrogen due to obesity contributes to an increased risk of ER+ PR+ postmenopausal breast cancer...
  4. ncbi request reprint Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol
    S Saji
    2nd Department of Surgery, Gifu University School of Medicine
    Jpn J Cancer Res 90:210-8. 1999
    ..These results suggest that MDM2 may regulate the expression of p53 in the steady state and in response to E2 in breast cancer cells, and imply a novel and important role of MDM2 during breast carcinogenesis...
  5. pmc Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane
    Shigehira Saji
    Department of Target Therapy Oncology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto, 606 8507, Japan
    BioDrugs 27:469-78. 2013
    ..Furthermore, pre-specified exploratory analyses suggest that particular patient subgroups may have greater therapeutic benefit with eribulin and may warrant further study to explore the potential mechanisms. ..
  6. ncbi request reprint Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer
    Shigehira Saji
    Department of Clinical Trials and Research, Breast Surgery, Tokyo Metropolitan Komagome Hospital, Honkomagome, Tokyo, Japan
    Oncogene 24:4531-9. 2005
    ..05, respectively). HDAC6 expression was an independent prognostic indicator by multivariate analysis (odds ratio = 2.82, P = 0.047). These results indicate the biological significance of HDAC6 regulation via estrogen signaling...
  7. ncbi request reprint Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer
    Shigehira Saji
    Department of Surgery and Breast Oncology, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Breast Cancer 11:129-33. 2004
    ....
  8. ncbi request reprint Clinical impact of assay of estrogen receptor beta cx in breast cancer
    Shigehira Saji
    Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Breast Cancer 9:303-7. 2002
    ..We conclude that, in order to better characterize breast cancers and design appropriate therapy for individual patients, assays for ER beta cx must be made available to clinicians...
  9. ncbi request reprint Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor
    Shigehira Saji
    Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, 113 8677 Tokyo, Japan
    Cancer Res 62:4849-53. 2002
    ..This is the first evidence that evaluation of ER(beta)cx along with PR may contribute to a better characterization of ER(alpha)-positive breast cancers...
  10. doi request reprint Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells
    Mariko Muta
    Department of Health and Dietetics, Faculty of Medical Health, Teikyo Heisei University, Tokyo, Japan
    Oncology 77:182-91. 2009
    ..We aimed to clarify the cytotoxic and inhibitory effects of these drugs on EPC...
  11. doi request reprint Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer
    Masahiro Takada
    Department of Surgery, Graduate School of Medicine, Kyoto University, Japan
    Breast 21:40-5. 2012
    ..We aimed to investigate predictive effect of BMI on clinical response to neoadjuvant therapy with exemestane in postmenopausal patients with primary breast cancer...
  12. doi request reprint Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast
    Michitaka Honda
    Department of Breast Surgery, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo, 113 8677, Japan
    Surg Today 41:328-32. 2011
    ..This is a retrospective study of patients in a single center with SCC or MSCC...
  13. doi request reprint Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach
    Masahiro Takada
    Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo ku, Kyoto, Japan
    Breast Cancer 18:64-7. 2011
    ..This case suggests that multidisciplinary therapy including an immunological approach might be a breakthrough in the treatment of refractory disease...
  14. doi request reprint Sex steroid hormones in pairs of tumor and serum from breast cancer patients and pathobiological role of androstene-3β, 17β-diol
    Naoko Honma
    Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
    Cancer Sci 102:1848-54. 2011
    ..The intratumoral increase of E2, but not E1, in hormone receptor-positive postmenopausal breast cancer tissue, as well as the proliferative role of Aenediol, was elucidated...
  15. pmc Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
    Masakazu Toi
    Faculty of Medicine, Kyoto University, Kyoto, Japan
    BMC Cancer 10:56. 2010
    ..Here we investigate the relationship between HER2 expression or HER2 homodimers and OS in a clinic-based population of patients with MBC selected primarily by IHC...
  16. ncbi request reprint [Predictors of axillary node metastasis at breast surgery after neoadjuvant chemotherapy in patients with pre- chemotherapy-sentinel node positive breast cancer]
    Hiromi Tokita
    Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
    Gan To Kagaku Ryoho 38:1639-45. 2011
    ..We investigated predictors for axillary node metastasis at breast surgery after neoadjuvant chemotherapy (NAC) in patients with pre-chemotherapy-sentinel node positive breast cancer...
  17. ncbi request reprint Estradiol stabilizes p53 protein in breast cancer cell line, MCF-7
    Naoki Okumura
    Second Department of Surgery, Gifu University School of Medicine, Gifu 500 8705, Japan
    Jpn J Cancer Res 93:867-73. 2002
    ..These results suggest that the ratio of the two MDM2 proteins, p90(MDM2) and p60(MDM2), may affect the accumulation of wild-type p53 protein in response to E2...
  18. ncbi request reprint A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer
    Masahiro Takada
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo 113 8677, Japan
    Int J Oncol 25:397-405. 2004
    ..These findings suggest that the alteration in growth kinetics revealed by CK18NE and MIB-1 might be a surrogate marker for predicting the survival benefit from chemotherapy in primary breast cancer...
  19. doi request reprint Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy
    Naoko Honma
    Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
    J Clin Oncol 26:3727-34. 2008
    ..A large and systematic study is needed to address these important issues...
  20. ncbi request reprint DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice
    Gaku Matsumoto
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Oncol Rep 12:281-5. 2004
    ..DFU treatment also resulted in the inhibition of angiogenesis, as well as decreased COX-2 expression. Results of this study suggest that inhibitory effects of DFU might be COX-2 dependent...
  21. doi request reprint Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition
    Masakazu Toi
    Department of Surgery Breast Surgery, Kyoto University, Kyoto, Japan
    Cancer Sci 102:858-65. 2011
    ..The 24-week aromatase inhibition provided preferable clinical benefits with significant reduction in Ki67 index. More precise mechanisms of the response need to be investigated...
  22. ncbi request reprint [Controversies in endocrine therapy for breast cancer]
    Masayo Kawakami
    Department of Surgery and Breast Oncology, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Gan To Kagaku Ryoho 31:181-7. 2004
    ..Further research concomitant with clinical trials may lead to a more reliable endocrine therapy modality in the treatment of breast cancer...
  23. doi request reprint Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast
    Naoko Honma
    Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
    APMIS 116:923-30. 2008
    ..ER-beta1 itself, independent of ER-alpha expression and tamoxifen treatment, seems to have a tumor-suppressive effect, at least in apocrine carcinomas. Further study of ER-beta1 is desired to optimize breast cancer treatment...
  24. ncbi request reprint A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients
    Eiji Suzuki
    Breast Group, Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center, Tokyo, Japan
    Clin Cancer Res 13:1875-82. 2007
    ....
  25. ncbi request reprint A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer
    Tomoyuki Aruga
    Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo 113 8677, Japan
    Oncol Rep 22:273-8. 2009
    ..These findings suggest that the number of FOXP3-positive cells identified during PSC represents a promising predictive factor that might also be an important therapeutic target for breast cancer...
  26. doi request reprint Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment
    Yasuhiro Suzuki
    Department of Surgery, Tokai University School of Medicine, Isehara, Japan
    Jpn J Clin Oncol 39:699-706. 2009
    ..This Phase II study was conducted to evaluate efficacy and safety of gemcitabine monotherapy in anthracycline and taxane pre-treated Japanese metastatic breast cancer patients...
  27. ncbi request reprint Protracted administration of weekly docetaxel in metastatic breast cancer
    Katsumasa Kuroi
    Department of Surgery, Showa University Toyosu Hospital, Tokyo 135 8577, Japan
    Oncol Rep 10:1479-84. 2003
    ..Thus, a weekly schedule of docetaxel at low dose maintains activity and is less myelosuppressive, however, one should be careful about cumulative toxicities...
  28. ncbi request reprint Early breast cancer
    Tomoyoshi Suzuki
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Tokyo 113 0025, Japan
    Int J Clin Oncol 11:108-19. 2006
    ..Another approach to keeping the disease under control is the elucidation of breast cancer's molecular biological features. Assessment of potential molecular targets can lead to early diagnosis and molecular targeted treatment...
  29. doi request reprint Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome
    Kenji Hashimoto
    Department of Breast Oncology and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Oncology 82:168-74. 2012
    ..Therefore, we launched this retrospective biomarker analysis to clarify the role of stem cells in relation with endocrine therapy in hormone receptor-positive breast cancer...
  30. ncbi request reprint Distinct promoter usage of mdm2 gene in human breast cancer
    Naoki Okumura
    Second Department of Surgery, Gifu University School of Medicine, Gifu 500 8705, Japan
    Oncol Rep 9:557-63. 2002
    ..Tumors with mutant p53 also showed expression of S-mdm2 in some cases. These results strongly suggest that other factor(s) is also implicated in the promoter usage of mdm2 gene in human breast cancer tissues...
  31. ncbi request reprint Impact of vasculogenesis on solid tumor growth in a rat model
    Mariko Muta
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo 113 8677, Japan
    Oncol Rep 10:1213-8. 2003
    ..Thus, our results suggest the importance of neovascularization by bone marrow-derived endothelial cells for the promotion of tumor growth...
  32. ncbi request reprint Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer
    Shigehira Saji
    Department of Surgery and Breast Oncology, Division of Clinical Trials and Research, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
    Oncology 72:330-7. 2007
    ....
  33. ncbi request reprint [The differences of standard therapy for breast cancer between Europe/America and Japan--chemotherapy, operation,and radiotherapy]
    Dai Kitagawa
    Dept of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
    Gan To Kagaku Ryoho 34:690-3. 2007
    ..However, there are still some differences due to the limited usages of anti-cancer drugs and supporting drugs. We would discuss about these issues in this paper...
  34. ncbi request reprint Clinical significance of estrogen receptor beta in breast cancer
    Shigehira Saji
    Department of Surgery and Breast Oncology, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, 113 8677, Tokyo, Japan
    Cancer Chemother Pharmacol 56:21-6. 2005
    ..A selective estrogen receptor modulator, which works as an antagonist of ERalpha and an agonist of ERbeta, may be a promising chemo-preventive treatment...
  35. ncbi request reprint Decision tree and paradigms of primary breast cancer: changes elicited by preoperative therapy
    Masakazu Toi
    Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, Tokyo Metropolitan Medical Center for Cancer and Infectious Diseases, 3 18 22 Honkomagome, Bunkyo ku, 113 8677 Tokyo, Japan
    Med Sci Monit 9:RA90-5. 2003
    ..For instance, if SNB is conducted before the treatment, the over-treatment issue can be eliminated. In this article, we will discuss the changes in decision-tree and paradigms for primary..
  36. ncbi request reprint Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity
    Katsumasa Kuroi
    Department of Surgery, Toyosu Hospital Showa University, 4 1 18 Toyosu, Koutou ku, Tokyo 135 8577, Japan
    Breast Cancer 10:10-4. 2003
    ..However, there is still much to learn about the role of weekly docetaxel in adjuvant and neoadjuvant therapy...
  37. ncbi request reprint Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma
    Hisashi Saji
    Breast Oncology, Tokyo Metropolitan Komagome Hospital, 3 18 22, Honkomagome, Bunkyo ku, 113 8677, Tokyo, Japan
    Cancer Lett 190:191-7. 2003
    ..This series did not demonstrate P-glycoprotein and nuclear YB-1 expression might be one of the useful prognostic marker of breast cancer...
  38. doi request reprint Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature
    Shigehira Saji
    Division of Clinical Trials and Research, Department of Breast Surgery and Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo ku, Tokyo, Japan
    Breast Cancer 15:262-9. 2008
    ..There were several reports showing the antiproliferative effect of SERMs for estrogen receptor-negative cells, such as glioma. There are still numerous possible applications for SERMs when their intrinsic nature is utilized...
  39. ncbi request reprint Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome
    Chikashi Nakanishi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
    Oncology 67:476-9. 2004
    ..To our knowledge, we are the first to show that a germline mutation causing PJS is combined with the loss of the homologous normal allele of LKB1/STK11 in breast cancer...
  40. ncbi request reprint [Current indications for mastectomy in patients with breast cancer]
    Chikashi Nakanishi
    Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
    Nihon Geka Gakkai Zasshi 103:821-4. 2002
    ..In dealing with the changes in the treatment algorithm, we need to select the appropriate surgical options flexibly...
  41. doi request reprint Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects
    Wenzhao Li
    Department of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Int J Biol Markers 28:117-30. 2013
    ..Although studies with these agents have met with limited clinical success, the field of MMPIs is still expanding, and generation of highly effective and selective MMPIs might be a promising direction of this research area. ..
  42. ncbi request reprint Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues
    Yutaka Yamamoto
    Department of Surgery II, Hospital, Kumamoto University Medical School, 1 1 1 Honjo, Kumamoto 860 8556, Japan
    Oncol Rep 10:791-6. 2003
    ..It may be useful to study the expression of aromatase and E1-STS using immunocytochemical analysis for understanding the tumor characteristics in breast cancer...
  43. ncbi request reprint Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes
    Nobuyuki Yoshida
    Division of Endocrinology, Saitama Cancer Center Research Institute, Saitama Cancer Center Hospital, Kita adachi gun, Saitama 362 0806, Japan
    Cancer Sci 95:496-502. 2004
    ....
  44. ncbi request reprint Involvement of androgen receptor in 17beta-estradiol-induced cell proliferation in rat uterus
    Zhang Weihua
    Departments of Medical Nutrition and Bioscience, Karolinska Institute, Novum, Huddinge, Stockholm S 141 86, Sweden
    Biol Reprod 67:616-23. 2002
    ..These results indicate an important role for AR in proliferation of the uterus, where estrogen and androgen do not represent separate pathways but are sequential steps in one pathway...
  45. ncbi request reprint Analysis of estrogen receptor expression in tissues
    Margaret Warner
    Karolinska Institute, Huddinge University Hospital, Novum, Huddinge, S 14186, Sweden
    Methods Enzymol 364:448-63. 2003
  46. ncbi request reprint Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study
    Reiko Suzuki
    The National Institute of Environmental Medicine, Division of Nutritional Epidemiology, Karolinska Institutet, Stockholm, Sweden
    J Natl Cancer Inst 97:1601-8. 2005
    ....
  47. ncbi request reprint Dietary fiber intake and risk of postmenopausal breast cancer defined by estrogen and progesterone receptor status--a prospective cohort study among Swedish women
    Reiko Suzuki
    The National Institute of Environmental Medicine, Division of Nutritional Epidemiology, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 122:403-12. 2008
    ..Our results suggest that dietary fiber intake from fruit and cereal may play a role in reducing breast cancer risk...
  48. ncbi request reprint Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies
    Reiko Suzuki
    Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 122:1832-41. 2008
    ..The observed positive associations with alcohol for ER+PR+ and ER+PR- tumors cannot be explained by estrogen-dependent pathway only. Further studies need to clarify the biological mechanisms...
  49. ncbi request reprint [Trastuzumab treatment for breast cancer]
    Hiroyasu Yamashiro
    Department of Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital
    Nihon Rinsho 62:1305-11. 2004
    ..The optimal duration and period of trastuzumab treatment are still unknown and result of large scale randomized trial will be expected...
  50. ncbi request reprint [Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer]
    Katsumasa Kuroi
    Dept of Surgery, Tokyo Metropolitan Komagome Hospital
    Gan To Kagaku Ryoho 29:55-60. 2002
    ..A biweekly schedule of paclitaxel seems to be feasible and effective in patients with advanced or recurrent breast cancer...
  51. ncbi request reprint A role for the androgen receptor in follicular atresia of estrogen receptor beta knockout mouse ovary
    Guojun Cheng
    Department of Medical Nutrition, Karolinska Institute, Novum, S 14186 Huddinge, Sweden
    Biol Reprod 66:77-84. 2002
    ....